---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-102134"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T19:07:08.442427+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price

## Summary
- Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.
- Has until Jan 3, 2025 to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Separate bid price deficiency: common stock below $1.00 for 30 consecutive business days; cure period until May 19, 2025.
- Both deficiencies have no immediate effect on listing, but failure to regain compliance could lead to delisting.
- Company evaluating options to regain compliance; no assurance of success.

## SEC filing metadata
- accession: 0001213900-24-102134
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024102134/0001213900-24-102134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024102134/ea0222513-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-102134
- JSON: https://secwatch.observer/filing/0001213900-24-102134.json
- Plain text: https://secwatch.observer/filing/0001213900-24-102134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.